Clinical Trials Insight: 700023107
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2008
At a glance
- Drugs NGD 4715 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Neurogen Corporation
- 14 Jan 2008 Based on results from the multiple dose ascending study, Neurogen has decided not to advance NGD 4715 into phase II testing, but will consider out-licensing its drug program for potential development with a partner.
- 11 May 2007 New trial record.